Healthcare tech company Omnicell (NASDAQ: OMCL) will be announcing earnings results this Tuesday before market hours. Here’s what to look for.
Omnicell met analysts’ revenue expectations last quarter, reporting revenues of $314 million, up 2.3% year on year. It was a mixed quarter for the company, with EBITDA guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ full-year EPS guidance estimates.
Is Omnicell a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Omnicell’s revenue to grow 12.9% year on year, improving from the 9.6% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Omnicell rarely misses Wall Street’s revenue estimates.
With Omnicell being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare technology stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.1% on average over the last month. Omnicell is up 16.4% during the same time .
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
